文献リスト

1）Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005; 11(7): 791-6

2）Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011; 17(5): 589-95

3）Dreux M, Dao Thi VL, Fresquet J, et al. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009; 5(2): e1000310

4）Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012; 18(2): 281-5

5）Romero-Brey I, Merz A, Chiramel A, et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 2012; 8(12): e1003056

6）Reiss S, Rebhan I, Backes P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe. 2011; 9(1): 32-45

7）Berger KL, Kelly SM, Jordan TX, et al. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol. 2011; 85(17): 8870-83

8）Tai AW, Salloum S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One. 2011; 6(10): e26300

9）Reiss S, Harak C, Romero-Brey I, et al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog. 2013; 9(5): e1003359

10）Bianco A, Reghellin V, Donnici L, et al. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog. 2012; 8(3): e1002576

11）Hsu NY, Ilnytska O, Belov G, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010; 141(5): 799-811

12）Machlin ES, Sarnow P, Sagan SM. Masking the 5ʼ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011; 108(8): 3193-8

13）Shimakami T, Yamane D, Jangra RK, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A. 2012; 109(3): 941-6

14）Li YP, Gottwein JM, Scheel TK, et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5ʼUTR. Proc Natl Acad Sci U S A. 2011; 108(12): 4991-6

15）Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327(5962): 198-201

16）Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368(18): 1685-94

17）Chatterji U, Bobardt M, Selvarajah S, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem. 2009; 284(25): 16998-7005

18）von Hahn T, Schiene-Fischer C, Van ND, et al. Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. Gastroenterology. 2012; 143(2): 439-47

19）Foster TL, Gallay P, Stonehouse NJ, et al. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J Virol. 2011; 85(14): 7460-4

20）Nag A, Robotham JM, Tang H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol. 2012; 86(23): 12616-24

21）Hopkins S, DiMassimo B, Rusnak P, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol. 2012; 57(1): 47-54

22）Neveu G, Barouch-Bentov R, Ziv-Av A, et al. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog. 2012; 8(8): e1002845

23）Menzel N, Fischl W, Hueging K, et al. MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 2012; 8(7): e1002829

24）Coller KE, Heaton NS, Berger KL, et al. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog. 2012; 8(1): e1002466

25）Herker E, Harris C, Hernandez C, et al. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med. 2010; 16(11): 1295-8

26）Li Q, Pène V, Krishnamurthy S, et al. Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med. 2013; 19(6): 722-9

27）Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7(8): 927-33

28）Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008; 48(6): 1761-8

29）Lacek K, Vercauteren K, Grzyb K, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol. 2012; 57(1): 17-23

30）Vogt A, Scull MA, Friling T, et al. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology. 2013; 444(1-2): 1-11

31）Bissig KD, Le TT, Woods NB, et al. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci U S A. 2007; 104(51): 20507-11

32）Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010; 120(3): 924-30

33）Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology. 2011; 140(4): 1334-44

34）Bility MT, Zhang L, Washburn ML, et al. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat Protoc. 2012; 7(9): 1608-17

35）Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011; 474(7350): 208-11

36）Dorner M, Horwitz JA, Donovan BM, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature. 2013. doi: 10.1038/nature12427. [Epub ahead of print]

37）Ploss A, Khetani SR, Jones CT, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A. 2010; 107(7): 3141-5

38）Podevin P, Carpentier A, Pène V, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroentero­logy. 2010; 139(4): 1355-64

39）Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012; 109(7): 2544-8

40）Roelandt P, Obeid S, Paeshuyse J, et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol. 2012; 57(2): 246-51

41）Wu X, Robotham JM, Lee E, et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 2012; 8(4): e1002617

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp